In a groundbreaking move, the FDA has green-lighted Flow Neuroscience’s FL-100 device, marking a new era for at-home depression treatment. Yes, you read that right—an actual device you can use in your living room to tackle major depressive disorder. This isn’t just some fancy gadget; it’s the first FDA-approved at-home brain stimulation device for adults suffering from moderate to severe MDD. No more endless waiting rooms or overpriced consultations.
The FDA has approved the FL-100, a revolutionary at-home device for treating major depressive disorder.
The approval came after the Empower phase 2 study showed that a jaw-dropping 58% of participants achieved remission after just 10 weeks. Sounds like a game-changer, right? The FL-100 works by delivering transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex. In plain English? It sends low-intensity electrical signals to help regulate mood.
Each session lasts 30 minutes, and you can either follow along with a digital app or have a clinician supervise you. The treatment protocol spans 12 weeks, and about 77% of users globally report symptom improvement within three short weeks. That’s impressive! The device has already been used by over 55,000 patients in Europe, the UK, and beyond. Now, it’s coming to the U.S. in the second quarter of 2026. But let’s not forget—this isn’t just for the treatment-resistant crowd. Anyone 18 or older can give it a shot. Additionally, the device received Breakthrough Device Designation in 2022, highlighting its potential impact in the field of mental health.
Of course, it’s not all rainbows and butterflies. Mild side effects like skin irritation and headache are possible, but nothing too severe has popped up in the approval data. So, it’s generally safe for home use.
With mental health care often feeling like an uphill battle, the FL-100 offers a non-drug alternative. It’s a new perspective in a world where pills have been the go-to solution for far too long. Just think—depression relief without the side effects of a pharmacy’s worth of medication. That’s something to cheer about. Additionally, the device is expected to launch at a price point between $500 and $800, making it an accessible option for many seeking relief.
